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Abstract
Background: Neurotensin has been found to promote colon carcinogenesis in rats and mice, and proliferation of
human colon carcinoma cell lines, but the mechanisms involved are not clear. We have examined signalling
pathways activated by neurotensin in colorectal and pancreatic carcinoma cells.
Methods: Colon carcinoma cell lines HCT116 and HT29 and pancreatic adenocarcinoma cell line Panc-1 were
cultured and stimulated with neurotensin or epidermal growth factor (EGF). DNA synthesis was determined by
incorporation of radiolabelled thymidine into DNA. Levels and phosphorylation of proteins in signalling pathways
were assessed by Western blotting.
Results: Neurotensin stimulated the phosphorylation of both extracellular signal-regulated kinase (ERK) and Akt in
all three cell lines, but apparently did so through different pathways. In Panc-1 cells, neurotensin-induced
phosphorylation of ERK, but not Akt, was dependent on protein kinase C (PKC), whereas an inhibitor of the b-
isoform of phosphoinositide 3-kinase (PI3K), TGX221, abolished neurotensin-induced Akt phosphorylation in these
cells, and there was no evidence of EGF receptor (EGFR) transactivation. In HT29 cells, in contrast, the EGFR tyrosine
kinase inhibitor gefitinib blocked neurotensin-stimulated phosphorylation of both ERK and Akt, indicating
transactivation of EGFR, independently of PKC. In HCT116 cells, neurotensin induced both a PKC-dependent
phosphorylation of ERK and a metalloproteinase-mediated transactivation of EGFR that was associated with a
gefitinib-sensitive phosphorylation of the downstream adaptor protein Shc. The activation of Akt was also inhibited
by gefitinib, but only partly, suggesting a mechanism in addition to EGFR transactivation. Inhibition of PKC blocked
neurotensin-induced DNA synthesis in HCT116 cells.
Conclusions: While acting predominantly through PKC in Panc-1 cells and via EGFR transactivation in HT29 cells,
neurotensin used both these pathways in HCT116 cells. In these cells, neurotensin-induced activation of ERK and
stimulation of DNA synthesis was PKC-dependent, whereas activation of the PI3K/Akt pathway was mediated by
stimulation of metalloproteinases and subsequent transactivation of the EGFR. Thus, the data show that the
signalling mechanisms mediating the effects of neurotensin involve multiple pathways and are cell-dependent.
Background
Due to the high prevalence of colorectal cancer [1], bet-
ter insight into regulatory mechanisms involved in cell
proliferation in this malignancy is needed, and might
ultimately lead to improved treatment. Several receptors
can mediate proliferogenic signals. Among these, G pro-
tein-coupled receptors (GPCRs) may induce mitogenic
signalling and have a role in cancer, including colorectal
and pancreatic cancer [2-4]. Moreover, activation of
GPCRs and receptor tyrosine kinases (RTKs) may act in
concert to enhance cellular proliferation. Thus, an
important question is how these signals are integrated
in the cells. * Correspondence: k.mueller@hotmail.no
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iating their effects via heterotrimeric G proteins (of either
the Gs, Gi, Gq, or G12/13 subtypes) [5,6]. While the role
of Gs-coupled prostanoid receptors in colon cancer cell
proliferation, apoptosis, andm i g r a t i o nh a sb e e ne x t e n -
sively studied [4], there is less information on the role of
Gq-coupled receptors in this malignancy. Stimulation of
these receptors leads to activation of phospholipase Cb
(PLCb) and thereby of protein kinase C (PKC), which
may be involved in tumorigenesis [7]. Elevated expression
of PKC bII has been found to be an early promotive
event in colon cancer development [8], and inhibition of
PKC b was found to decrease proliferation and induce
apoptosis in colon carcinoma cells [9].
Neurotensin is a peptide that binds to GPCRs. It is
mainly formed in the central nervous system and by
endocrine cells of the digestive tract, where it acts as a
paracrine and endocrine modulator in a variety of gut
functions, including vascular smooth muscle activity,
gastrointestinal motility, gastric emptying, and intestinal,
pancreatic, and biliary secretions [10]. In addition, neu-
rotensin stimulates growth of the intestinal mucosa
under physiological and pathological conditions [10,11]
and has been found to promote azoxymethane-induced
colon carcinogenesis in rats and mice [12,13]. Neuroten-
sin has also been implicated in the progression of can-
cers of the pancreas, breast, lung, and prostate
[10,11,14]. Three subtypes of neurotensin receptors have
been cloned [15]. The high affinity NTSR1 receptor and
the low affinity NTSR2 receptor both belong to the
GPCR family, while the NTSR3/sortilin receptor is a
nonspecific receptor with a single transmembrane
domain [15,16]. The pharmacological and signalling
properties of the NTSR2 receptor, which exerts its
effects mainly in the central nervous system, are incom-
pletely understood, and appear to be dependent on cell
type and species [16]. The peripheral effects of neuro-
tensin appear to be mediated largely by NTSR1, which
activates PLCb [14,16]. Experiments using a specific
antagonist or knockdown of the NTSR1 using short
interfering RNA suggest that NTSR1 mediates the
effects of neurotensin on cancer cells, although NTSR3/
sortilin, which is often coexpressed in cancer cells, may
modulate NTSR1 signalling [14,16]. Splice variants of
the NTSR1 were recently detected in prostate cancer
cell lines, however, no functional studies of these have
been conducted [17]. Recent data have suggested that
the NTSR1 receptor gene may be a downstream target
of the extracellular signal-regulated kinase (ERK) and
Tcf/b-catenin pathways [18,19], and increased expres-
sion of NTSR1 during progression of colon tumorigen-
esis has been reported [20,21].
Neurotensin has been found to stimulate proliferation
of certain colon carcinoma cell lines [10,22]. Reports on
intracellular signalling leading to proliferation induced
by neurotensin in some other cell types have suggested
the involvement of PKC-dependent activation of ERK
and protein kinase D (PKD) [10,23-27], and either
dependence or independence of epidermal growth factor
receptor (EGFR) transactivation [23-25]. In the pancrea-
tic cancer cell line Panc-1, DNA synthesis induced by
neurotensin was independent of EGFR transactivation
[23], whereas in the prostate cancer cell line PC-3, neu-
rotensin stimulated mitogenesis by a PKC-dependent
transactivation of EGFR [24]. In colon carcinoma cell
lines neurotensin has been found to activate ERK, as
well as PKC, Akt, and nuclear factor B( N F - B) path-
ways [28-31]. Furthermore, neurotensin induced phos-
phorylation and inactivation of glycogen synthase kinase
(GSK), leading to cyclin D1 expression, through
mechanisms that were at least partly dependent on PKC
[29]. Neurotensin has also been found to induce a
proinflammatory tumour microenvironment and pro-
mote cancer cell invasion through pathways that
involved NF-B, PKC, ERK, and the sodium-proton
exchanger 1 (NHE1) [14,31-33].
T h ea i mo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t es o m e
of the intracellular signalling pathways involved in mito-
genesis induced by neurotensin in human colorectal
cancer cells, by examining the HCT116 and HT29 lines
and comparing them with Panc-1 cells. The results sug-
gested that while neurotensin acted predominantly
through PKC in Panc-1 cells and via EGFR transactiva-
tion in HT29 cells, it used both these pathways in
HCT116 cells. In the latter cells neurotensin-induced
activation of ERK was mediated largely by PKC, while
neurotensin-induced activation of Akt was independent
of PKC but involved transactivation of the EGFR, appar-
e n t l yb yaC a
2+-dependent mechanism. Neurotensin-
induced DNA synthesis was mediated mainly by PKC.
Methods
Chemicals
Dulbecco’s modified Eagle’s medium, N-(2-hydroxyethyl)
piperazine-N’-(2-ethanesulfonic acid (Hepes), penicillin
and streptomycin were from Gibco (Grand Island, NY).
Neurotensin, 12-O-tetradecanoylphorbol-13-acetate
(TPA), thapsigargin, epidermal growth factor (EGF), and
wortmannin were obtained from Sigma-Aldrich (St.
Louis, MO). [2-[1-(3-dimetylaminopropyl)-1H-indol-3-
yl]-maleimide] (GF109203X), 4-(3-chloroanilino)-6,7-
dimethoxyquinazoline (tyrphostin AG1478), 2’-amino-3’-
methoxyflavone (PD98059, and N-[(2R)-2 (hydroxami-
docarbonylmethyl)-4-methylpentanoyl]-L-tryptophan
methylamide (GM6001/Galardin) were from Calbiochem
(San Diego, CA). 7-Methyl-2-(4-morpholinyl)-9-[1-(phe-
nylamino)ethyl]-4H-pyrido[1,2-a] pyrimidin-4-one
(TGX-221) was obtained from Cayman Chemical (Ann
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obtained from Bachem (Bubendorf, Switzerland). 4-Qui-
nazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-
6-[3-4-morpholin)propoxy] (gefitinib) was a gift from
Astra Zeneca (Cheshire, UK), and cetuximab was kindly
provided by Merck KgaA (Darmstadt, Germany). [6-
3H]
thymidine (20-30 Ci/mmol) and myo-[2-
3H]inositol
( 1 5 . 0C i / m m o l )w e r ef r o mA m e r s h a mB i o s c i e n c e s
(Buckinghamshire, UK). Antibodies against phosphory-
lated Akt
Ser473, total Akt, dually phosphorylated
ERK
Thr202/Tyr204, phospho-EGF receptor
Tyr1173,a n d
phospho-Shc
Tyr239/240 were obtained from Cell Signal-
ing Technology (Boston, MA). Anti-ERK and anti-Shc
antibodies were obtained from Upstate (Billerica, MA).
EGFR antibody (1005) was obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Secondary antibo-
dies were purchased from Bio-Rad Laboratories (Her-
cules, CA) and Licor Biosciences (Lincoln, NE). All
other chemicals were of analytical quality. Stock solu-
tions of test compounds were prepared in DMSO (TPA,
thapsigargin, wortmannin, PD98059, GM6001, TGX221,
gefitinib) or 0.9% NaCl (neurotensin, GF109203X). EGF
was dissolved in 4 mM HCl, and TGFa in 4 mM HCl
containing 1% bovine serum albumin from Sigma
Aldrich (St. Louis, MO). Cetuximab was dissolved in
phosphate-buffered saline (PBS). When solutions con-
taining DMSO were used, the final concentration of
DMSO was kept as low as possible.
Cell culture
Human colorectal cancer cell lines HCT116 and HT29,
and pancreatic adenocarcinoma cell line Panc-1 were
obtained from ATCC (Manassas, VA). The cells were
maintained in Dulbecco’s modified Eagle’s medium con-
taining 1 g/l glucose (or 4.5 g/l for Panc-1) supplemen-
ted with 10% horse serum (10% fetal bovine serum for
Panc-1 cells), penicillin (67 μg/ml), streptomycin (100
μg/ml) and 2 mM glutamine (4 mM for Panc-1). Cells
were plated onto Costar plastic culture wells (Corning
Life Sciences, Acton, MA) at a density of 50 000 cells/
cm
2 (25 000 cells/cm
2 in the case of Panc-1 cells) in
serum-containing medium. The cultures were kept in
9 5 %a i r / 5 %C O 2 at 37°C. After 24 hours the medium
was replaced with serum-free medium and the cells
were cultured for 24 hours before stimulation with
agonists.
Measurement of DNA synthesis
Neurotensin, TPA, and inhibitors of PKC and EGF
receptor were added to serum-starved HCT116 cells as
described in the figure legends, and [
3H]thymidine was
added 12 hours after stimulation. Serum-starved HT29
and Panc-1 cells were stimulated for 21 hours with
neurotensin and EGF before [
3H]thymidine was added.
The cells were harvested after three hours pulsing with
[
3H]thymidine, and DNA synthesis was measured as
the amount of radioactivity incorporated into DNA as
previously described [34]. Briefly, medium was
removed, and cells were washed twice with 0.9% NaCl.
The cellular material was dissolved with 1.5 ml of 0.5
N NaOH for 3 hours at 37°C, collected, mixed with 1.5
ml H2O, and precipitated with 0.75 ml 50% trichloroa-
cetic acid (TCA). The acid-precipitable material was
transferred to glass fiber filters (GF/C Whatman, GE
Healthcare, UK) and washed twice with 5.0 ml 5%
TCA, followed by liquid scintillation counting of the
filters in a Packard Tri-Carb liquid scintillation
counter.
Inositol phosphate accumulation
Cells were labelled with [
3H]inositol, 2.5 μCi/ml for 24
hours in serum-free medium. Medium was removed 30
minutes before agonist stimulation and replaced with
Krebs-Ringer-Hepes buffer pH 7.4, containing 10 mM
glucose and 15 mM LiCI. HCT116 cells were stimu-
lated with neurotensin for 30 minutes, and the reaction
was stopped by removing buffer and adding 1 ml ice-
cold 0.4 M perchloric acid. Samples were harvested
and neutralized with 1.5 M KOH, 60 mM EDTA, 60
mM Hepes, in the presence of Universal indicator. The
neutralized supernatants were applied on columns con-
taining 1 ml Dowex AG 1-X8 resin (Bio-Rad Labora-
tories, Hercules, CA), and inositol phosphates were
eluted with 10 ml 1 M ammonium formate/0.1 M for-
mic acid.
Immunoblotting
Aliquots with ~30 000 cells (total cell lysate prepared in
Laemmli or RIPA buffer) were electrophoresed on 6-
12% (w/v) polyacrylamide gels. This was followed by
protein electrotransfer to nitrocellulose membranes and
immunoblotting with antibodies against phospho-Akt,
total Akt, phospho-ERK1/2, total ERK, phospho-EGFR,
total EGFR, phospho-Shc, and total Shc, respectively.
Immunoreactive bands were visualized with enhanced
chemiluminescence using LumiGLO (KPL Protein
Research Products, Gaithersburg, MD), or infrared ima-
ging using Odyssey Infrared Imaging System supplied by
Licor Biosciences (Lincoln, NE), respectively.
Statistical analyses
R e s u l t sa r ee x p r e s s e da sm e a n s±s t a n d a r de r r o ro ft h e
mean (S.E.M). DNA synthesis data were analyzed by
one-way ANOVA, and post tests using Bonferroni cor-
rection to compare groups, using GraphPad Prism
(version 5.01, GraphPad Software, San Diego, Califor-
nia, USA). Results were considered significant when p
< 0.05.
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Neurotensin stimulates DNA synthesis in HCT116 and
Panc-1 cells
Neurotensin has been reported to act as a mitogen in
certain colon cell lines [10,22]. We found that neuroten-
sin dose-dependently induced DNA synthesis in
HCT116 cells, reaching a two- to three-fold increase as
compared to basal levels (Figure 1A, 2C). In contrast,
addition of EGF only slightly increased DNA synthesis,
which is in agreement with previous data and might be
explained by an autocrine production of EGFR ligands
by these cells, masking the effects of exogenously added
EGF [35-37]. Furthermore, concomitant stimulation of
HCT116 cells with neurotensin and EGF did not induce
any synergistic or additive effect on DNA synthesis. In
HT29 cells, EGF dose-dependently (data not shown) sti-
mulated DNA synthesis, whereas neurotensin had no
significant effects, neither alone nor in combination with
EGF (Figure 1B). In Panc-1 cells, both neurotensin and
EGF stimulated DNA synthesis, as reported previously
[25], (Figure 1C).
Role of PKC in neurotensin-induced DNA synthesis
The high affinity NTSR1 receptor is known to activate
PLC [15]. Neurotensin was previously shown to elevate
intracellular Ca
2+ in HCT116 cells [38], and in our
experiments neurotensin strongly and dose-dependently
stimulated accumulation of inositol phosphates in these
cells (Figure 2A). This strongly implicates PLC in the
mechanisms of the cellular response of HCT116 cells to
neurotensin. We next pretreated HCT116 cells with the
PKC inhibitor GF109203X, and Figure 2B shows that
this blocker strongly reduced DNA synthesis. It was also
noted that the stimulatory effect of neurotensin on
DNA synthesis was of the same magnitude as the effect
of the direct PKC activator tetradecanoylphorbol acetate
(TPA) (Figure 2C). Together, the results suggest a major
r o l eo ft h eP L C / P K Cp a t h w a yi nt h es t i m u l a t i o no f
DNA synthesis by neurotensin in these colon cancer
cells.
Role of PKC in neurotensin-induced phosphorylation of
ERK
Neurotensin induced a marked, rapid, and sustained
phosphorylation of ERK in HCT116 cells (Figure 3A),
which appeared to plateau at a concentration of 3-10
nM (Figure 3B). Direct activation of PKC by TPA also
stimulated ERK phosphorylation (Figure 3C). The phos-
phorylation of ERK in response to neurotensin and TPA
was strongly reduced by pretreatment of the cells with
GF109203X (Figure 3C). In contrast, EGF-stimulated
ERK phosphorylation was not affected by the PKC
blocker (Figure 3C). In agreement with previous data
[23] neurotensin stimulated ERK phosphorylation in a
*
*
#
*
#
ABC
*
#
*
Figure 1 Effect of EGF and neurotensin alone and in combination on DNA synthesis. Quiescent HCT116 (A), HT29 (B), and Panc-1 (C) cells
were treated with 5 nM EGF, 1 μM neurotensin (NT), or a combination of both agents. [3 H]thymidine was added 12 h (HCT116) or 21 h after
addition of agonists. The cells were harvested three hours after adding [3 H]thymidine and DNA synthesis was assessed as described in Methods.
The results are presented as per cent of control values of three (HCT116) or six (HT29, Panc-1) independent experiments. Error bars indicate S.E.
M. * Significantly different (p < 0.05) from control; # significantly different from control (p < 0.05), but not from neurotensin alone (A) or EGF
alone (B, C).
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whereas in HT29 cells, ERK phosphorylation was only
slightly attenuated by the PKC inhibitor (Figure 4B).
Thus, in agreement with previous results from other
cells where neurotensin stimulated ERK phosphorylation
and DNA synthesis in a PKC-dependent manner
[23-25], our data indicate that neurotensin-induced ERK
phosphorylation in HCT116 cells is PKC-dependent.
Role of EGFR in Akt phosphorylation induced by
neurotensin
EGF induced a marked phosphorylation of Akt in
HCT116 cells, indicating activation of the phosphoinosi-
tide 3-kinase (PI3K) pathway (Figure 3C). Neurotensin
also stimulated phosphorylation of Akt, although not as
strongly as EGF (Figure 3C). The effect of neurotensin
on Akt first appeared after 3 min, while ERK phosphor-
ylation was evident already at 1 min (Figure 3A).
Furthermore, unlike the data indicating a PKC-mediated
activation of ERK, neurotensin-induced phosphorylation
of Akt was not affected by inhibition of PKC and was
not mimicked by TPA (Figure 3C).
We next examined the ability of neurotensin to induce
tyrosine phosphorylation of EGFR in HCT116 cells. Fig-
ure 5A shows that treating the cells with neurotensin or
EGF resulted in phosphorylation of the EGFR. Although
the effect of neurotensin was clearly less than that of
EGF, the phosphorylation induced by both these ago-
nists was blocked by pretreatment with the EGFR tyro-
sine kinase inhibitor gefitinib (Figure 5A). Moreover, we
found that neurotensin stimulated phosphorylation of
Shc (Figure 5B), which is an adaptor protein that binds
to, and is phosphorylated by, active RTKs [39,40]. Taken
together, these results suggest that the EGFR can be
transactivated by neurotensin in HCT116 cells.
Pretreatment with gefitinib strongly attenuated neuro-
tensin-induced phosphorylation of Akt in HCT116 cells
(Figure 5C). In these experiments, TGFa was used as
the EGFR ligand, and the effect of TGFa on Akt phos-
phorylation was completely abolished by gefitinib. Neu-
rotensin also induced Akt phosphorylation in HT29 and
Panc-1 cells (Figure 4). Whereas this effect was abol-
ished by pretreatment with gefitinib in HT29 cells (Fig-
ure 4B), neither gefitinib nor the PKC inhibitor
GF109203X inhibited neurotensin-stimulated Akt phos-
phorylation in Panc-1 cells (Figure 4A).
Neurotensin-induced transactivation of the EGFR is partly
mediated by shedding of extracellular ligands
Evidence from many cell types indicates that transactiva-
tion of the EGFR induced by GPCRs may be mediated by
the activation of cell surface proteinases, resulting in
*
AB C
Figure 2 Role of PKC in neurotensin-stimulated DNA synthesis in HCT116 cells. A, Dose-response curve for the effect of neurotensin (NT)
on accumulation of [3 H] inositol phosphates in the presence of 15 mM LiCl. Cells were labeled with [3 H]-inositol for 24 hours before NT was
added to quiescent cells at the concentrations indicated. The reaction was stopped after 30 minutes, and inositol phosphates were extracted
and analyzed as described in Methods. Results are presented as per cent of control values ± S.E.M., n = 3. B, Effect of the PKC inhibitor,
GF109203X (GF) on basal and NT-induced DNA synthesis. Quiescent cells were pretreated with 3.5 μM GF109203X for 30 min before stimulation
with 1 μM NT. Based on dose-response curves for the effect of GF109203X on NT-induced DNA synthesis we found 3.5 μM to be the maximum
concentration tolerated by our cells (data not shown). DNA synthesis was determined by [3 H]thymidine incorporation as described in the
legend of figure 1. Results are presented as per cent of control values of seven independent experiments. Error bars indicate S.E.M. * Significantly
different from control (p < 0.05). C, Dose-response curves for the effects of NT or TPA on DNA synthesis. Quiescent cells were treated with the
respective agonists in the concentrations indicated. DNA synthesis was determined by [3 H]thymidine incorporation as described in the legend
of figure 1. The results are presented as per cent of control values ± S.E.M. of six independent experiments.
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cellular mechanisms involving kinases such as Src and
Pyk2 [43,44]. To explore further the mechanism of the
gefitinib-sensitive Akt phosphorylation induced by neuro-
tensin, we examined the effect of cetuximab, an antibody
which binds to the extracellular domain of the EGFR and
thereby blocks the ability of ligand-induced activation. As
expected, EGF-stimulated phosphorylation of both Shc
and Akt was completely inhibited by cetuximab (Figure
6A). Cetuximab pretreatment also blocked neurotensin-
stimulated Shc phosphorylation, suggesting the involve-
ment of a ligand-dependent mechanism. Neurotensin-
induced phosphorylation of Akt was also inhibited by
cetuximab, but only partially. We next pretreated the cells
with GM6001, a broad-spectrum inhibitor of matrix and
metalloproteinases (MMPs) and a disintegrin and metallo-
proteinases (ADAMs). Pretreatment with GM6001 did not
affect the effect of neurotensin on ERK, but markedly
reduced neurotensin-induced phosphorylation of Akt (Fig-
ure 6B). These results support a role of release of EGFR
ligand(s) in neurotensin-stimulated phosphorylation of
EGFR and Akt. However, since neither cetuximab nor
GM6001 completely abolished the effect of NT on Akt
phosphorylation, it seems likely that additional mechan-
isms are operating. As expected, the effect of exogenous
EGF was insensitive to GM6001 (Figure 6B).
Role of Ca
2+ in activation of PI3K/Akt
The results above suggest that neurotensin-stimulated
phosphorylation of Akt in HCT116 cells is mediated, at
pAkt
Akt
- +     - +      - +      - +    GF109203X
pERK
C          NT         TPA       EGF
pERK
pAkt
Akt
1        3 5        15        30         60       min 
- +    - +    - +    - +     - +     - +     NT
A
C
B
pERK
pAkt
GAPDH
0     10-9 3x10-9 10-8 NT, M 10-7 10-6
Figure 3 Time-course and PKC-dependency of ERK and Akt
phosphorylation in HCT116 cells. A, Time-course of neurotensin-
induced phosphorylation of ERK and Akt. Quiescent cells were
stimulated with 1 μM neurotensin (NT) for the times indicated. Cells
were harvested for subsequent Western analysis as described in
Methods. Results represent one typical of three independent
experiments. B, Effect of increasing concentrations of neurotensin on
phosphorylation of ERK and Akt. Quiescent cells were stimulated with
increasing concentrations of neurotensin for five minutes. Cells were
harvested for subsequent Western analysis as described in Methods.
Results represent one typical of three experiments. C, Role of PKC in
NT-induced phosphorylation of ERK and Akt. Quiescent cells were
pretreated with vehicle (0.9% NaCl) or 3.5 μM GF109203X for 30 min,
before stimulation with 1 μM NT, 1 μM TPA, or 5 nM EGF for five min
and then harvested for subsequent Western analysis. Results
represent one typical of eight independent experiments.
Control   Gefitinib         GF
pERK
pAkt
ERK
- +      - +       - +       NT
Panc-1
HT29
pERK
pAkt
ERK
- +      - +      - +      - +     NT
Control       GF       DMSO   Gefitinib
A
B
Figure 4 Role of PKC and EGF receptor in neurotensin-induced
signalling in HT29 and Panc-1 cells. Panc-1(A) and HT29 (B) cells
were pretreated with vehicle (0.9% NaCl or 0.5% DMSO), 3.5 μM
GF109203X, or 1 μM gefitinib for 30 min before stimulation with 1
μM neurotensin (NT) for 5 min. Cells were harvested for subsequent
Western analysis as described in Methods. Results represent one
typical of four independent experiments.
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search for mechanisms that mediate the release of EGFR
ligands in HCT116 cells, we next examined the role of
intracellular Ca
2+. Thapsigargin, which increases the
intracellular Ca
2+-level by inhibiting the SERCA pump
[45], induced phosphorylation of Shc, ERK and Akt (Fig-
ure 7A). Furthermore, like the effect of neurotensin, the
effect of thapsigargin on Shc phosphorylation was abol-
ished by pretreatment with cetuximab, while the effect
on Akt phosphorylation was attenuated, which suggests
the involvement of Ca
2+ in the response of the PI3K
pathway to neurotensin. Further experiments showed
that the effects of neurotensin and thapsigargin on Akt
phosphorylation were sensitive to chelating Ca
2+-inhibi-
tors (data not shown). However, we have so far not
been able to show that this effect is selective, as EGF-
stimulated Akt phosphorylation was also attenuated by
Ca
2+-inhibitors. In contrast to the findings in HCT116
cells, thapsigargin did not stimulate phosphorylation of
Akt in Panc-1 cells (data not shown). However, in these
cells neurotensin-stimulated Akt phosphorylation was
abolished by pretreating the cells with TGX-221, an
inhibitor of PI3Kb [46] (Figure 7B). This indicates that
PI3Kb is involved in neurotensin-induced activation of
Akt in Panc-1 cells.
Signalling pathways involved in neurotensin-induced DNA
synthesis in HCT116 cells
The above results suggest a role for the PLC/PKC path-
way in the DNA synthesis induced by neurotensin in
HCT116 cells. Furthermore, consistent with a role of
ERK in the mitogenic response, pretreatment of the
cells with the MEK inhibitor PD98059 (50 μM) strongly
reduced both basal and neurotensin-induced DNA
synthesis (Figure 8A). Although stimulation with EGF
only slightly affected DNA synthesis in the cells (Figure
1), we examined the possibility that activation of the
EGFR pathway might play a role in neurotensin-induced
mitogenic stimulation. We found that inhibition of the
EGFR tyrosine kinase activity by gefitinib or AG1478
resulted in a reduction of both basal and neurotensin-
induced DNA synthesis (Figure 8B). Furthermore, a role
for the PI3K pathway in the neurotensin-induced mito-
genesis was likely since the DNA synthesis was reduced
by the PI3K inhibitor wortmannin (Figure 8C).
Discussion
In the present study, we have found that neurotensin-
induced signalling in colon carcinoma cells involves
both EGFR-dependent and -independent pathways. In
HCT116 cells, stimulation by neurotensin of ERK phos-
phorylation and DNA synthesis is mediated by PKC,
whereas Akt phosphorylation induced by neurotensin is
dependent on EGFR-mediated signalling.
In agreement with previous studies in human pancrea-
tic cancer cells (Panc-1) [23,25] we found that neuroten-
sin-induced ERK activation and DNA synthesis in the
colon cancer cells HCT116 was mainly dependent on
PKC and did not involve EGFR transactivation. Thus,
the stimulatory effect of neurotensin and TPA on DNA
synthesis was of the same magnitude, and stimulation of
both DNA synthesis and ERK phosphorylation by neu-
rotensin was inhibited by pretreatment with the PKC
blocker GF109203X. Furthermore, while neurotensin sti-
m u l a t e dA k tp h o s p h o r y l a t i o ni na nE G F R - d e p e n d e n t
-       -      -        +      -       -      +    Gefitinib
EGFR 
pEGFR
      NT                   EGF  A 
 -       +      -        +      -        +     Gefitinib 
pAkt 
pERK 
ERK 
   C           TGF          NT  C 
pShc 
Shc 
 -      -      -      +      +     +     Gefitinib 
C   EGF NT    C   EGF   NT  B 
Figure 5 Role of EGFR in neurotensin-induced signalling in
HCT116 cells. A, Phosphorylation of the EGFR residue 1173 induced
by neurotensin (NT) and EGF. Quiescent cells were pretreated with
vehicle (0.5% DMSO) or 10 μM gefitinib for 30 min before
stimulation with 1 μM NT or 5 nM EGF for five min. Cells were
harvested for subsequent Western analysis as described in Methods.
Because of the strong EGFR phosphorylation induced by EGF, we
also show the same blot overexposed. Results represent one typical
of three independent experiments. B, Phosphorylation of Shc
induced by NT and EGF in cells pretreated with vehicle or gefitinib.
Results represent one typical of three independent experiments. C,
Phosphorylation of ERK and Akt induced by NT (1 μM) and TGFa
(10 nM) in cells pretreated with vehicle or 10 μM gefitinib for 30
min before stimulation. Results represent one typical of four
independent experiments.
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Page 7 of 12manner, TPA did not induce phosphorylation of Akt in
HCT116 cells. In prostate cancer cells, neurotensin also
stimulated ERK phosphorylation in a PKC-dependent
manner, but in these cells activation of PKC mediated
transactivation of the EGFR [24].
We did not find that EGF stimulated DNA synthesis
significantly in HCT116 cells. A plausible explanation is
the autocrine production of TGFa and other ligands,
leading to constitutive activation of EGFR in HCT116
cells [47-49]. It was previously reported that while exo-
genous addition of EGF had no effect on DNA synth-
esis, due to the production of TGFa [35], the EGFR was
not saturated by the autocrine ligand(s) and could be
further activated by exogenous EGF, resulting in integrin
a2 expression, cell adhesion, and micromotion [37]. It is
likely that basal DNA synthesis reflects the effect of this
constitutive EGFR activation, consistent with the finding
that inhibition of EGFR activity with gefitinib reduced
both basal and neurotensin-stimulated DNA synthesis.
However, neurotensin still enhanced DNA synthesis
compared to its corresponding control.
While neurotensin-induced phosphorylation of ERK
and stimulation of DNA synthesis in HCT116 cells were
dependent on PKC, we found phosphorylation of Akt
induced by neurotensin to be independent of PKC.
Moreover, the lack of effect of TPA on phosphorylation
of Akt further strengthens the notion that PKC is not
involved in activation of Akt in HCT116 cells. Instead,
neurotensin-induced phosphorylation of Akt was depen-
dent on EGFR activation, and this effect was mimicked
by elevation of intracellular Ca
2+ induced by thapsigar-
gin. Our results thus strongly suggest that neurotensin-
induced phosphorylation of ERK and Akt is mediated by
different pathways. In contrast, phosphorylation of both
ERK and Akt induced by neurotensin was mediated by
PKC-dependent EGFR transactivation in prostate cancer
cells [24]. Furthermore, in HT29 cells, both ERK and
Akt phosphorylation induced by neurotensin was abol-
ished by pretreatment with gefitinib (Figure 4) or cetuxi-
mab (data not shown). These observations are in line
with previous studies in HT29 cells, demonstrating that
activation of PAR1 and PAR2 receptors led to transacti-
vation of the EGFR through matrix metalloproteinase-
dependent release of TGFa [50,51]. The different time
course of ERK and Akt phosphorylation in HCT116
cells also supports the involvement of different
pathways.
Conflicting results have been reported on the effect of
neurotensin on EGFR phosphorylation in different cells
[23,24]. Thus, while neurotensin did not induce transac-
tivation of the EGFR in Panc-1 cells [23], PKC-depen-
dent transactivation of the EGFR mediated the
mitogenic effect of neurotensin on prostate cancer cells
[24]. We found that neurotensin induced phosphoryla-
tion of the EGFR and the adaptor protein Shc in
HCT116 cells, and that inhibiting the EGFR with cetuxi-
mab or gefitinib strongly reduced neurotensin-induced
phosphorylation of Akt. These results strongly suggest
that the EGFR is transactivated by neurotensin in
HCT116 cells and that this transactivation is involved in
pShc
Shc
pAkt
Akt
- +       - +       - +      Cetuximab
CNTEGF
pShc
pERK
- +        - +       - +      GM6001
pAkt
ERK
CNTEGF
A B
Figure 6 Role of EGFR in neurotensin-induced phosphorylation of ERK, Akt, and Shc in HCT116 cells. A, Effect of EGFR inhibition on
neurotensin (NT)-induced signalling. Quiescent cells were pretreated with 25 μg/ml cetuximab for 30 min before stimulation with 1 μMN To r
10 nM EGF for five min. Cells were harvested for subsequent Western analysis as described in Methods. Results represent one typical of four
independent experiments. B, Effect of protease inhibition on NT-induced phosphorylation of downstream proteins. Quiescent cells were
pretreated with 10 μM GM6001 for 30 min prior to stimulation with 1 μM NT or 10 nM EGF for five min. Results represent one typical of six
independent experiments.
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Page 8 of 12mediating the Akt phosphorylation stimulated by neuro-
tensin. Since the PI3K/Akt pathway is important in sev-
eral regulations besides cell proliferation, such as
promoting cell survival by enhancing resistance to apop-
tosis [52-56], the EGFR-mediated activation by neuro-
tensin may have significant roles in the malignant
phenotype in these cells.
It is unclear why neurotensin activates different path-
ways in the different the cell lines. It is known that
HCT116 and Panc-1 cells both harbour a KRAS muta-
tion, while HT29 cells have a mutant BRAF.F u r t h e r -
more, HT29 and HCT116 cells harbour mutations in
the catalytic a polypeptide of phosphoinositide-3-kinase,
(PIK3CA), and HT29 cells also have mutated p53 http://
www.sanger.ac.uk/genetics/CGP/CellLines/, [57]. While
pERK
pAkt
ERK
C         EGF       NT        C        EGF        NT
DMSO               TGX
pERK
pShc
Shc
pAkt
GAPDH
C     NT  Thap   C    NT   Thap  
Cetuximab A
B
Figure 7 Role of calcium in phosphorylation of ERK, Akt, and
Shc. A, Effect of thapsigargin (Thap) and neurotensin (NT) on
phosphorylation of ERK, Akt, and Shc in HCT116 cells. Quiescent
cells were pretreated with vehicle (0.9% NaCl) or cetuximab (25 μg/
ml) for 30 min before stimulation with the vehicle (0.5% DMSO), 1
μM NT, or 1 μM Thap for five min. Cells were harvested for
subsequent Western analysis as described in Methods. Results
represent one typical of three independent experiments. B, Effect of
PI3Kb inhibitor on NT-stimulated ERK and Akt phosphorylation in
Panc-1 cells. Quiescent cells were pretreated with vehicle (0.5%
DMSO) or 1 μM TGX-221 for 30 min before stimulation with 10 nM
EGF or 1 μM neurotensin (NT) for 5 min. Cells were harvested for
subsequent Western analysis as described in Methods. Results
represent one typical of four experiments.
A
C
B
*
#
*
* *
#
#
*
*
*
#
Figure 8 Signalling pathways involved in neurotensin-
stimulated DNA synthesis in HCT116 cells. A, Effect of MEK
inhibition on basal and neurotensin (NT)-induced DNA synthesis.
Quiescent cells were pretreated with vehicle (0.5% DMSO) or 50 μM
PD98059 (PD) for 30 min before stimulation with the vehicle (0.9%
NaCl) or 1 μM NT. Data are presented as per cent of control values
of six independent experiments. Error bars indicate S.E.M. *
Significantly different from vehicle-treated control (p < 0.05),
#significantly different from control cells pretreated with PD98059 (p
< 0.05). B, Effect of EGFR kinase inhibitors on DNA synthesis induced
by neurotensin. Quiescent cells were pretreated for 30 min with
vehicle (0.5% DMSO), 10 μM gefitinib (Gef), or 10 μM AG1478 prior
to stimulation with 1 μM NT. Data are presented as per cent of
control values of four (AG1478) or seven (gefitinib) independent
experiments. Error bars indicate S.E.M. * Significantly different from
vehicle-treated control (p < 0.05), #significantly different from
control cells pretreated with gefitinib or AG1478 (p < 0.05). C, Effect
of phosphoinositide 3-kinase inhibition on DNA synthesis induced
by neurotensin. Quiescent cells were pretreated for 30 min with
vehicle (0.5% DMSO) or 1 μM wortmannin (WM) prior to stimulation
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Page 9 of 12it is known that mutations in KRAS, BRAF and PIK3CA
may determine the responsiveness to targeted therapies
such as EGFR, MEK or mTOR inhibitors [53,57,58], the
consequences of these mutations for neurotensin signal-
ling in the different cell lines are not obvious. Whereas
we found that neurotensin treatment stimulated Akt
phosphorylation in the three cell lines examined, an ear-
lier report using NTSR1-transfected AV12 cells found
that neurotensin inhibited basal and EGF- or insulin-sti-
mulated Akt phosphorylation, which was ascribed to a
negative regulation mediated through Gq [59]. It has
been found that classical PKC isoforms mediate feed-
back inhibition of EGFR transactivation by Gq-coupled
receptor agonists [60]. The degree of EGFR-induced
transactivation involvement in signalling by neurotensin
may thus depend on the strength of PKC-mediated feed-
back inhibition in different cells. In this context, it is of
interest that HCT116 cells have a higher expression of
the classical isoform PKCbII than HT29 cells [61].
Interestingly, while the results showed that EGFR acti-
vation was required for neurotensin-stimulated phos-
phorylation of Akt, we did not obtain complete
inhibition of this effect by pretreatment with neither
GM6001, cetuximab or gefitinib. Contrary to this, Akt
phosphorylation induced by direct activation of the
EGFR by TGFa or EGF was completely suppressed by
gefitinib or cetuximab. Also, neurotensin-stimulated Shc
phosphorylation was completely suppressed. One possi-
ble explanation is that neurotensin also might induce
release of ligands that activate ErbB3 or ErbB4 recep-
tors. The HCT116 cells have been found to release sev-
eral ligands that activate the ErbB receptor family
[62-64]. The lack of complete inhibition induced by
GM6001 pretreatment could imply that EGFR transacti-
vation could also be induced independently of ligand
shedding by an intracellular calcium-mediated mechan-
ism, possibly involving Pyk2 or Src [43,44]. Alternatively,
neurotensin might induce transactivation of the insulin-
like growth factor-1 receptor (IGF-1R), as observed in
human colonic epithelial cells [65]. Another possibility
is that neurotensin induces Akt phosphorylation
through activation of subtypes of PI3K that are directly
activated by GPCRs [66,67]. In fact, HCT116 cells have
been found to express PI3Kb [52], which is activated by
GPCRs [66]. TGX-221, an inhibitor of PI3Kb [46], did
not affect neurotensin-stimulated Akt phosphorylation
when used alone, but it further suppressed neurotensin-
stimulated phosphorylation of Akt when combined with
gefitinib (data not shown). Thus, it is possible that mul-
tiple pathways activated by neurotensin might converge
on Akt phosphorylation in a partially redundant man-
ner. In contrast, neurotensin-stimulated phosphorylation
of Akt in Panc-1 cells was abolished by pretreatment
with TGX-221, indicating involvement of PI3Kb in this
cell line. Although several mechanisms may thus be
involved in mediating the effect of neurotensin on
with 1 μM NT. DNA synthesis was determined by [3 H]thymidine
incorporation as described in the legend of figure 1. Data are
presented as per cent of control values of six independent
experiments. Error bars indicate S.E.M. * Significantly different from
vehicle-treated control (p < 0.05), #significantly different from
control cells pretreated with wortmannin (p < 0.05).
Figure 9 Summary of pathways activated by neurotensin in
HCT116, HT29, and Panc-1 cells.
Müller et al. BMC Cancer 2011, 11:421
http://www.biomedcentral.com/1471-2407/11/421
Page 10 of 12phosphorylation of Akt in HCT116 cells, our results
suggest that ligand shedding, which may be dependent
on Ca
2+ elevation, and the resulting activation of the
EGFR is a main pathway.
Conclusions
While acting predominantly through PKC in Panc-1
cells and via EGFR transactivation in HT29 cells, neuro-
tensin used both these pathways in HCT116 cells (Fig-
ure 9). Taken together, our results suggest that, in
HCT116 cells, neurotensin-induced DNA synthesis and
phosphorylation of ERK is mediated mainly by PKC
independently of EGFR transactivation. In addition, neu-
rotensin induces phosphorylation of Akt via activation
of metalloproteinases and subsequent shedding of
ligands that activate the EGFR.
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